2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Sunday, November 10, 2019

4:30PM-6:00PM: Abstract Number: 927

Efficacy and Safety of Filgotinib for Patients with Rheumatoid Arthritis Naïve to Methotrexate Therapy: FINCH3 Primary Outcome Results

3S109: RA – Treatments II: Novel Treatments for RA (927–932)

4:30PM-6:00PM: Abstract Number: 908

Epidemiology and Presentation of Sarcoidosis with and Without HIV Infection

3S104: Miscellaneous Rheumatic & Inflammatory Disease I: Expanding the Spectrum of Clinical Features in Rheumatological Disorders (903–908)

4:30PM-6:00PM: Abstract Number: 923

First Cardiovascular Event in Rheumatoid Arthritis: Do Patients with Venous Thromboembolism Have a Different Risk Profile Than Patients with Atherosclerotic Cardiovascular Disease?

3S108: RA – Diagnosis, Manifestations, & Outcomes II: Cardiovascular Comorbidities (921–926)

4:30PM-6:00PM: Abstract Number: 919

Free Interlukin-18: A New Promising Biomarker for Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome

3S107: Pediatric Rheumatology – Clinical I: Systemic JIA (915–920)

4:30PM-6:00PM: Abstract Number: 894

Frequency, Severity and Costs of Flares Increase with Disease Severity in Newly Diagnosed Systematic Lupus Erythematous: A Real-World Cohort Study, United States, 2004–2015

3S101: Epidemiology & Public Health II: SLE (892–897)

4:30PM-6:00PM: Abstract Number: 924

Highly-sensitive Cardiac Troponin-I and Beta-2-Glycoprotein-I IgA Antibodies Inform the Utility of Screening and Follow-up Non-invasive Coronary Atherosclerosis Evaluation and Optimize Cardiovascular Risk Assessment in Rheumatoid Arthritis

3S108: RA – Diagnosis, Manifestations, & Outcomes II: Cardiovascular Comorbidities (921–926)

4:30PM-6:00PM: Abstract Number: 896

Hydroxychloroquine Use and Cardiovascular Events Among Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis

3S101: Epidemiology & Public Health II: SLE (892–897)

4:30PM-6:00PM: Abstract Number: 889

Identification of Genetic Variants Associated with Erosive Hand Osteoarthritis Using Pedigrees from a State-Wide Population-Based Cohort

3S105: Osteoarthritis & Joint Biology – Basic Science (886–891)

4:30PM-6:00PM: Abstract Number: 922

Improved Incidence of Cardiovascular Disease in Patients with Incident Rheumatoid Arthritis in 2000s: A Population-Based Cohort Study

3S108: RA – Diagnosis, Manifestations, & Outcomes II: Cardiovascular Comorbidities (921–926)

4:30PM-6:00PM: Abstract Number: 946

Improvements in Disease Activity and Quality of Life for up to 64 Weeks in Patients with Behçet’s Syndrome: Results from a Phase III Study

3S112: Vasculitis – Non-ANCA-Associated & Related Disorders I: Miscellaneous Disorders (945–950)

4:30PM-6:00PM: Abstract Number: 925

Incidence of Dementia and Association with Cardiovascular Disease and Risk Factors in Rheumatoid Arthritis – Analysis of a National Claims Database

3S108: RA – Diagnosis, Manifestations, & Outcomes II: Cardiovascular Comorbidities (921–926)

4:30PM-6:00PM: Abstract Number: 921

Indicators of Actionable Levels of Atherosclerosis in RA Patients Who Appear to Have Low or Intermediate Atherosclerotic Cardiovascular Risk Based on Standard Risk Algorithms

3S108: RA – Diagnosis, Manifestations, & Outcomes II: Cardiovascular Comorbidities (921–926)

4:30PM-6:00PM: Abstract Number: 884

Interferon-Alpha Disrupts Multiple B Cell Tolerance Mechanisms in 3H9 Mice

3S100: B Cell Biology & Targets in Autoimmune & Inflammatory Disease (880–885)

4:30PM-6:00PM: Abstract Number: 909

Is Long-term High-intensity Strength Training Beneficial or Harmful for Knee Osteoarthritis Patients? The Strength Training and Arthritis Trial (START)

3S106: Osteoarthritis – Clinical I: Innovations (909–914)

4:30PM-6:00PM: Abstract Number: 910

Is There Any Role for Opioids in the Management of OA?

3S106: Osteoarthritis – Clinical I: Innovations (909–914)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].